预约演示

更新于：2026-04-09

Paclitaxel

紫杉醇

更新于：2026-04-09

概要

基本信息

药物类型

小分子化药

别名

EmPAC、LDE-paclitaxel、NanoPac

+ [77]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤感染消化系统疾病+ [12]

在研适应症

晚期胃癌转移性胰腺腺癌转移性乳腺癌+ [216]

非在研适应症

异戊酸血症急性淋巴细胞白血病食管腺癌+ [203]

原研机构

National Institutes of Health

在研机构

National Cancer InstituteToLymph Inc.

AstraZeneca PLC

+ [54]

非在研机构

The Gynecologic Oncology GroupHQ Specialty Pharma Corp.Hoffmann-La Roche, Inc.

+ [50]

权益机构

深圳市康哲药业有限公司

沈阳三生制药有限责任公司

Hanmi Pharmaceutical Co., Ltd.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

艾滋病相关性卡波西肉瘤乳腺癌卵巢癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,846

项与紫杉醇相关的临床试验

NCT07346196

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

开始日期2027-02-07

申办/合作机构

The University of Chicago

NCT07281417

/ Recruiting临床2期IIT

Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study

This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.

开始日期2026-11-24

申办/合作机构

National Cancer Institute

NCT07195734

/ Recruiting临床2期IIT

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the treatment of patients with PD-L1 positive head and neck squamous cell carcinoma that has come back and spread to nearby tissue or lymph nodes after a period of improvement (locally recurrent) or is persistent. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Salvage surgery is surgery that takes place to remove tumor tissue after a failure of other treatment. High risk patients also receive radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding chemotherapy or chemo-immunotherapy to standard salvage surgery may kill more tumor cells than salvage surgery alone in patients with PD-L1 positive locally recurrent or persistent head and neck squamous cell carcinoma.

开始日期2026-10-09

申办/合作机构

National Cancer Institute

100 项与紫杉醇相关的临床结果

登录后查看更多信息

100 项与紫杉醇相关的转化医学

登录后查看更多信息

100 项与紫杉醇相关的专利（医药）

登录后查看更多信息

51,927

项与紫杉醇相关的文献（医药）

2026-12-31·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

2026-12-31·ANNALS OF MEDICINE

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials

Review

作者: Du, Zhiyan ; Xu, Yixin ; Wang, ZhiLong ; Fan, Chao ; Jiang, Zhihui ; Wu, Tingting ; Zheng, Yingying ; Lv, Mingming ; Pan, Ying ; Adilijiang, Adilai. ; Bai, Bingxin ; Xie, Xiang ; Deng, Changjiang

BACKGROUND:

Coronary small-vessel disease (SVD) remains challenging for percutaneous coronary intervention (PCI) because small lumens magnify restenosis and ischemic risk. Multiple devices are available, yet their comparative performance is uncertain. This study evaluated and ranked PCI strategies for SVD.

METHODS:

A systematic review and network meta-analysis was conducted in accordance with PRISMA. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to 15 August 2025. Eligible studies were English-language randomized controlled trials enrolling adults with angiographic SVD defined as reference vessel diameter ≤3.0 mm, comparing PCI strategies, and reporting target lesion revascularization (TLR), binary restenosis (BR), or myocardial infarction (MI). A frequentist random-effects network meta-analysis generated odds ratios (ORs) with 95% confidence intervals (CIs) and treatment rankings using the surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-nine trials including 14,503 patients met the criteria. For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). For BR (32; 6,468), SES, ZES, and paclitaxel-coated balloons (DCB-PTX) ranked highest (95.0%, 80.0%, and 78.3%). For MI (37; 11,602), SES, DCB-PTX, and ZES ranked highest (79.0%, 78.7%, and 68.5%). Representative effects showed SES reduced TLR versus bare-metal stents (BMS) (OR, 0.25; 95% CI, 0.15-0.43) and MI versus BMS (OR, 0.41; 95% CI, 0.21-0.79). Conventional approaches such as BMS, plain old balloon angioplasty (POBA), and gold-plated balloon angioplasty (GPBA) ranked lowest across outcomes.

CONCLUSION:

SES provides the most consistent clinical benefit for coronary SVD. ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

5,628

项与紫杉醇相关的新闻（医药）

21 小时之前

·药时代

500万美元！英派药业收到Eikon里程碑付款

合作机会来了！药时代BD团队现有优质项目：高选择性，高亲合性，口服透脑多靶点小分子，适应症为孤独症谱系障碍（ASD）。目前临床II期进行中，安全性特征明确，具备开发成其他（贴剂、长效）剂型的潜力。了解详情，请点击这里：用于治疗孤独症谱系障碍（ASD）的临床II期多靶点透脑性小分子 | 药时代BD项目请感兴趣的公司立即联系：药时代BD团队 BD@drugtimes.cn 备注项目代号：DT-20260325-122 2026年4月9日，英派药业宣布已收到Eikon Therapeutics, Inc. (以下简称“EIKON”)支付的500万美元里程碑付款。该笔款项依据双方2023年5月围绕IMP1734及其他PARP1选择性抑制剂签署的合作与许可协议支付，其中核心管线IMP1734（大中华区以外代号：EIK1003）顺利推进至临床II期阶段，触发约定的该里程碑付款条件。 IMP1734为公司自主研发的高活性新一代PARP1选择性抑制剂，目前正在全球开展用于治疗晚期实体瘤的临床I/II 期试验，评估其作为单药及联合疗法的疗效。通过选择性靶向PARP1并减少对PARP2的影响，PARP1选择性抑制剂提供了一种更精准的治疗方案，具有更高的安全性，尤其显著降低了血液学毒性。凭借耐受性提升与更宽的治疗窗，IMP1734可支持更灵活的联合用药方案，有望拓展至既往非选择性PARP1/2抑制剂无法涉足的治疗场景。 IMP1734对PARP1的选择性较PARP2高出648倍以上，有望进一步降低血液学毒性、提升安全性、提高体内药物暴露量，并具备更广泛的抗肿瘤药物联合用药的机会。在I期剂量爬坡阶段，IMP1734单药治疗展现出优异的药代动力学特征，不良事件多为轻度，可控且具备自限性。公司同时推进多项IMP1734联合用药队列研究，目前IMP1734联合阿比特龙+泼尼松、以及联合紫杉醇的临床试验队列均在开展中。从全球行业现状来看，成功获得里程碑付款并非易事。根据美国市场调研机构SRS ACQUIOM于2023年9月发布的报告，过去9年间，生物制药领域的BD交易中，超过60%的里程碑未能达成。仅以2023年为例，当年里程碑达成率仅为22%。在实际交易中，药企最终通过里程碑获得的收入通常仅占协议总金额的3%左右。正因如此，越来越多的中国创新药企正在国际合作的深水区中，逐个触碰并点亮那些预设的“里程碑节点”，更显可贵。 2025年12月1日，百利天恒发布公告，称其子公司SystImmune已收到由百时美施贵宝（BMS）支付的2.5亿美元里程碑付款（实际到账金额须扣除银行手续费）。这笔里程碑款项源于2025年9月30日公布的一项关键临床进展：全球II/III期注册临床试验IZABRIGHT-Breast01（评估EGFR/HER3双抗ADC BL-B01D1）达成里程碑，正式触发了双方合作协议中的首笔近期或有付款条件。值得一提的是，这不仅是百利天恒与BMS合作的重要兑现节点，也创下了迄今为止中国创新药“出海”交易中，单个ADC资产首笔里程碑付款的最高纪录。 2026年1月9日，百奥泰发布公告称，近日已收到Hikma支付的1000万美元里程碑付款（实际到账金额扣除银行手续费）。2021年8月，百奥泰与Hikma签署授权许可与商业化协议，将BAT2206（乌司奴单抗）注射液在美国市场的独家商业化权益授权给Hikma。协议首付款为2000万美元，里程碑付款总额达1.3亿美元。 2026年2月3日，先声药业宣布曾于2025年1月13日刊发公告，披露本集团附属公司已与AbbVie Inc.附属公司就研究性新候选药物SIM0500订立海外许可选择权协议。根据该协议条款，本集团将从AbbVie收取首付款，以及最高可达10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用费。继此前已收到该协议项下首付款后，先声药业已于近期进一步收到来自AbbVie支付的4000万美元款项。该款项的支付，体现了先声药业与AbbVie围绕推进SIM0500临床开发合作的积极进展。 2026年2月3日，英矽智能宣布其与美纳里尼合作的抗癌新药MEN2501（原项目代号ISM）在I期临床试验中完成首例患者给药，触发3900万港元里程碑付款。这是继2025年7月获得2340万港元开发和监管里程碑付款后，该项目取得的又一进展。此前，英矽智能以5.5亿美元合作总额（首付款2000万美元）将MEN2501项目对外授权给美纳里尼，全资子公司Stemline Therapeutics。当前，随着一批中国创新药企接连收到里程碑付款，其意义已远远超出补充现金流本身。首先，这是研发能力的硬核证明。在国际合作的深水区中，一家又一家中国企业逐个触碰并点亮预设的节点，说明中国创新药的质量正经受住全球最严苛的检验。其次，里程碑付款有助于拉动股价、提振投资者信心。每一次里程碑的达成，都意味着此前的一项潜在风险已被成功化解。持续到账的里程碑款项，实则是管线估值不断攀升的外在信号。更深层的信号在于：中国创新药的价值兑现逻辑，正从“拿钱签约”向“长期分账”演进。首付款只是入场券、是“信任票”；而源源不断的里程碑付款，以及未来可期的销售分成，才是真正的“分红票”。这意味着，一家中国Biotech的成功，不再仅仅依赖于融资或卖管线，而是可以通过与国际巨头深度绑定，分享一款药物从研发、临床到最终上市销售的全周期价值。这是一种更稳定、也更可持续的生存与发展模式。参考资料： 1.https://mp.weixin.qq.com/s/7s6tU_x8uu8Pu6cMNXWBLg 2.3900万港元！英矽智能收到美纳里尼里程碑付款 3.4000万美元！先声药业收到艾伯维三抗TCE里程碑付款 4.百利天恒2.5亿美元到账！创下单个ADC资产首笔最高里程碑付款记录 5.当里程碑款开始兑现（公众号：写意君） 6.其他公开资料封面图来源：药时代砍价10亿美元！SEC文件曝光67亿美元并购案隐情 2026-04-08 29亿美元并购引争议，分析师：卖亏了！ 2026-04-07 III期临床失利反成催化剂！迭代产品能否挑落TED守擂者？ 2026-04-04 加征100%关税！特朗普签署药品关税行政令 2026-04-03 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

引进/卖出临床2期临床1期

22 小时之前

·ioncology

HER2研究者说胃癌篇 | 彭智教授：从循证更新到实战经验，DESTINY-Gastric04研究有望改写《CSCO 胃癌诊疗指南》HER2阳性胃癌二线标准

点击蓝字，关注我们编者按：自曲妥珠单抗开启胃癌抗HER2治疗时代以来，HER2阳性胃癌的二线治疗难有进展。2025年5月美国临床肿瘤学会（ASCO）年会及《新英格兰医学杂志》同步披露的DESTINY-Gastric04研究宣告德曲妥珠单抗（T-DXd）挑战二线标准雷莫西尤单抗联合紫杉醇（RAM+PTX）取得突破。2026年1月，基于该研究，中国国家药品监督管理局（NMPA）正式批准了新型靶向HER2 ADC德曲妥珠单抗（T-DXd）二线治疗HER2阳性胃癌适应症，使T-DXd成为了中国当前首个且唯一的胃癌二线抗HER2治疗策略，填补了国内空白。在即将于4月24-25日召开的“2026中国临床肿瘤学会（CSCO）指南会”上，《CSCO胃癌诊疗指南》也会迎来更新。为此，《肿瘤瞭望》特别在“HER2研究者说胃癌篇”栏目采访了DESTINY-Gastric04研究PI、北京大学肿瘤医院彭智教授，请他分享T-DXd的临床表现及实战经验，前瞻指南可能的更新要点，为HER2阳性胃癌二线治疗提供参考意见。 01 肿瘤瞭望：作为DESTINY-Gastric04研究的参研单位，请您分享一下临床实践中应用T-DXd二线治疗胃癌的经验。彭智教授北京大学肿瘤医院非常有幸参与了DESTINY-Gastric04临床研究[1,2]。与此同时，我们还在沈琳教授的带领下，参与了中国三线桥接的DESTINY-Gastric06研究[3]，故而在T-DXd的胃癌适应症获批之前，已经积累了一定的应用经验。 DESTINY-Gastric04研究主要针对HER2阳性胃癌患者的二线治疗。该研究显示，T-DXd单药二线治疗较标准的RAM+PTX方案可显著提升中位总生存期（mOS），为14.7个月 vs 11.4个月，降低了30%的死亡风险（HR=0.70，95%CI：0.55-0.90，P=0.0044）；同时也显著提升了中位无进展生存期（mPFS），为6.7个月 vs 5.6个月（HR=0.74，95%CI：0.59-0.92，P=0.0074）；并一定程度上改善了安全性，T-DXd≥3级治疗期间不良事件更低，为50.0% vs 54.1%，治疗导致的中断和减量比例也更少[1,2]。无论是作为研究者、还是临床医生，我们在临床实践中均可看到患者治疗线数越靠前，其肿瘤负荷越低、体力状态越好。在历经DESTINY-Gastric06研究后，再看DESTINY-Gastric04研究，我们对T-DXd的安全性担忧变得更少，T-DXd在疗效及安全性的表现也比既往三线研究更好。在未来，我们要规范应用T-DXd，让HER2阳性晚期胃癌二线治疗的生存时间和生活质量得到进一步提升。 02 肿瘤瞭望：不久前，基于DESTINY-Gastric04研究，T-DXd获批了HER2阳性胃癌二线治疗适应症，请您谈谈该适应症获批的意义及影响。彭智教授北京大学肿瘤医院从2025年5月ASCO年会与《NEJM》同步披露DESTINY-Gastric04研究阳性结果，到2026年1月NMPA正式批准HER2阳性胃癌二线治疗适应症，获批速度不可谓不快。该适应症的获批将为临床实践中二线应用T-DXd提供坚实的依据，使晚期HER2阳性胃癌患者疗效得到有效提升。 T-DXd并不会止步于二线。既往DESTINY-Gastric03研究已在一线初步探索了T-DXd联合治疗对疗效提升的作用[4]。如今，包括我中心在内的全国几十中心正在开展T-DXd联合免疫治疗及化疗一线治疗HER2阳性胃癌DESTINY-Gastric05研究[5]，此外还有其他T-DXd一线相关探索正在进行中。T-DXd已然改变了HER2阳性晚期胃癌的临床实践，我们非常期待它能为患者带来更长期的生存获益，乃至实现治愈。 03 肿瘤瞭望：CSCO指南会即将开幕，请您预测一下，新版的《CSCO 胃癌诊疗指南》哪些领域将迎来重磅更新？彭智教授北京大学肿瘤医院过去的一年里，胃癌领域新药物、新组合、新理念取得了许多进展。比如针对HER2阳性胃癌二线治疗的DESTINY-Gastric04研究以及T-DXd相应适应症的获批，毫无疑问会改变指南，成为标准的治疗推荐，惠及更多患者。此外，SHR-1701、ZW25、KN026等一系列新药也可能基于相应进展获得相关推荐。在其他领域，如影像、病理、内镜、外科等方面，新版指南也将补充一些细节内容。我们对指南修订的目标是尽可能依据当前循证医学证据，为临床提供规范化的治疗标准，从而使更多胃癌患者得到规范治疗、取得更多获益。参考文献：（滑动查看） [1]Shitara K, Van Cutsem E, Gümüş M, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336-348. doi:10.1056/NEJMoa2503119 [2]Shitara K, Gumus M, Pietrantonio F, et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.2025 ASCO.LBA4002. [3]Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404. Published 2025 Aug 11. doi:10.1016/j.eclinm.2025.103404 [4]Yelena Y. Janjigian et al. Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).. J Clin Oncol 43, 448-448(2025). doi:10.1200/JCO.2025.43.4_suppl.448. [5]Janjigian Y, Smyth E, Shen L, et al. DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. ESMO Gastrointestinal Oncology, 2026; 11. 彭智教授博士，博士生导师北京大学肿瘤医院主任医师，北京大学博雅青年学者国家级青年人才项目获得者中国抗癌协会胃癌专委会委员中国抗癌协会肿瘤转移专委会委员中国抗癌协会肿瘤精准治疗委员会委员 CSCO胃癌专家委员会委员兼秘书 CSCO肿瘤营养治疗专家委员会委员中国免疫学会临床免疫分会委员北京癌症防治学会胃癌防治专委会主委北京癌症防治学会消化道精准治疗专委会副主任委员相关推荐 1 沈琳教授：德曲妥珠单抗获NMPA批准HER2阳性胃癌二线治疗适应症，抗HER2治疗再塑胃癌生存新高度 2 一图读懂丨T-DXd获批HER2阳性胃癌二线治疗适应症的前世今生 3 HER2研究者说胃癌篇丨张小田教授：再树胃癌抗HER2里程碑，德曲妥珠单抗新适应症革新胃癌二线治疗格局 4 HER2研究者说胃癌篇丨刘天舒教授：改写临床实践，德曲妥珠单抗成为中国首个且唯一的胃癌二线抗HER2靶向治疗策略 5 HER2研究者说胃癌篇 | 王风华教授：概览HER2阳性胃癌二线治疗发展，德曲妥珠单抗从理论到实践树立治疗新标准 6 HER2研究者说胃癌篇 | 应杰儿教授：把握HER2阳性胃癌治疗前沿与经验，德曲妥珠单抗二线疗效、安全双获益将改写格局（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果ASCO会议抗体药物偶联物CSCO会议

2026-04-09

·英派药业

IMPACT Therapeutics Receives $5.0 Million (US) Milestone Payment from EIKON Therapeutics

SHANGHAI, China, April 9, 2026—IMPACT Therapeutics (“IMPACT”) today announced that it has received a milestone payment of US$5.0 million from Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“EIKON”). The payment was triggered by the advancement of IMP1734 (also known as EIK1003 outside Greater China), one of the PARP1-selective inhibitors covered under the collaboration and license agreement between the two parties signed in May 2023, into Phase II clinical development. IMP1734 was discovered by IMPACT’s scientists, and is a highly potent, next-generation PARP1-selective inhibitor, currently being evaluated as monotherapy and as combination therapies in a global Phase I/II trial for advanced solid tumors. By selectively targeting PARP1 while sparing PARP2, PARP1-selective inhibitors may offer a more refined therapeutic approach with improved safety, particularly reduced hematologic toxicity. This enhanced tolerability and broader therapeutic window may potentially allow for more flexible combination strategies, potentially enabling use in treatment settings previously inaccessible to PARP1/2 inhibitors. IMP1734 has shown over 648-fold selectivity for PARP1 over PARP2, which may potentially translate to lower hematologic toxicity, improved safety, higher exposure, and broad opportunities to combine with other anti-tumor agents. In Phase I dose escalation studies, IMP1734 monotherapy shows a favorable pharmacokinetics (PK) profile and is well tolerated with mostly low-grade AEs that are manageable and/or self-limiting. We are also investigating IMP1734 in multiple combination regimens, with cohorts evaluating IMP1734 in combination with Abiraterone and Prednisone and with weekly Paclitaxel currently ongoing. Dr. Sui Xiong Cai, CEO of IMPACT, commented: The receipt of this milestone payment underscores the significant progress in our partnership. We’re excited to work closely with our partner EIKON to accelerate the global development of this program, with the goal of bringing new treatment options to patients as soon as possible. IMPACT will focus on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. About the Collaboration In May 2023, IMPACT and EIKON entered into an exclusive global licensing and collaboration agreement. Under the agreement, EIKON holds the exclusive rights to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1-selective inhibitors in all territories outside of Greater China. About IMP1734 IMP1734 is a novel PARP1-selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. Overall, phase I studies demonstrate hematologic toxicity to be uncommon, and clinical activity was observed at most doses tested, as evidenced by target lesion size reduction and durable responses. In addition, tolerability and efficacy are being evaluated in combination with Abiraterone and Paclitaxel, respectively, and results of these combination studies will be disclosed at future medical meetings. Additional information about the clinical trials of IMP1734 can be found at https://clinicaltrials.gov/study/NCT06253130. About Eikon Therapeutics Eikon Therapeutics is dedicated to advancing breakthrough therapies through the purposeful integration of science and engineering. Its research tools, including its proprietary SMT system, leverage Nobel Prize-winning super-resolution microscopy, bespoke automation, advanced data science, and software engineering to visualize and measure the real-time movement of proteins in living cells, with the goal of developing important innovative medicines to address serious unmet medical needs. About IMPACT Therapeutics Founded in 2009, we are a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. We have in-house discovered and developed one of the most comprehensive and advanced SL franchises and are one of only three companies with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1-selective inhibitors worldwide. Our core product, Senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for OC “all-comers” in China in January 2025, and is reimbursable for OC 1L “all-comers” since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC “all-comers” in China, setting a new benchmark in this class. Our continued growth is powered by an integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform. Our major clinical pipeline drug candidates include the PARP1/2 inhibitor Senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors. For additional information, please visit www.impacttherapeutics.com IMPACT Therapeutics Contact: +86 21 6841 1121 IR@impacttherapeutics.com PR@impacttherapeutics.com

100 项与紫杉醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00491	紫杉醇	L01CD01	DB01229

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期胃癌	中国	DAE HWA PHARM Co., Ltd.	2024-09-19
晚期胃癌	中国	上海海和药物研究开发股份有限公司	2024-09-19
转移性胰腺腺癌	欧盟	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	冰岛	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	列支敦士登	Accord Healthcare SLU	2024-01-05
转移性胰腺腺癌	挪威	Accord Healthcare SLU	2024-01-05
铂类耐药性原发性腹膜癌	欧盟	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	冰岛	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	列支敦士登	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	挪威	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	欧盟	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	冰岛	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	挪威	Inceptua SA	2018-11-20
铂敏感性输卵管癌	欧盟	Inceptua SA	2018-11-20
铂敏感性输卵管癌	冰岛	Inceptua SA	2018-11-20
铂敏感性输卵管癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性输卵管癌	挪威	Inceptua SA	2018-11-20
生殖细胞瘤	日本	Bristol Myers Squibb Co.	2013-02-21
生殖细胞瘤	日本	Clinigen KK	2013-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	申请上市	欧盟	Accord Healthcare SLU	2023-11-09
转移性胰腺癌	临床3期	中国	上海谊众药业股份有限公司	2025-01-21
高级别胶质瘤	临床3期	中国	浙江大学	2024-04-01
HEGF2阴性乳腺癌	临床3期	中国	上海谊众药业股份有限公司	2023-09-25
皮肤鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
转移性头颈部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
喉鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
口腔鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02654119 (CTgov)	临床2期	HER2阳性乳腺癌	20	Laboratory Biomarker Analysis+Trastuzumab+Cyclophosphamide+Paclitaxel	築鹹鹽鏇積糧鑰廠網廠 = 壓蓋窪鹹鑰齋廠衊淵襯壓廠憲鹹顧鏇願鹽簾獵 (遞窪鬱醖醖製齋憲齋淵, 選齋憲鹽夢艱獵憲壓膚 ~ 網鏇醖餘壓夢鹽餘壓蓋) 更多	-	2026-03-23
NCT03315364 (OPTIMAL, Pubmed) 人工标引	临床3期	转移性HER2阴性乳腺癌 \| 复发性HER2阴性乳腺癌 HER2 Negative	549	DHP107	窪餘窪壓蓋繭襯膚淵積(壓網襯壓淵齋積窪構簾) = 繭醖鏇鹽範鹹窪艱糧襯鹹鑰餘獵範餘構夢膚積 (壓築願廠鏇願積鏇壓觸 ) 更多	非劣	2026-03-13
				Paclitaxel	窪餘窪壓蓋繭襯膚淵積(壓網襯壓淵齋積窪構簾) = 艱築齋築襯廠齋齋簾憲鹹鑰餘獵範餘構夢膚積 (壓築願廠鏇願積鏇壓觸 ) 更多
NCT03179904 (CTgov)	临床2期	HER2阳性乳腺癌 \| HER2阳性转移性乳腺癌 \| 晚期乳腺癌	17	trastuzumab+FASN inhibitor TVB-2640+paclitaxel (Cohort A)	艱醖築築蓋膚獵襯繭鏇 = 簾艱鬱築鹽觸構鬱醖願願構艱鏇憲衊積構餘積 (鹹壓鹹網廠糧鑰積廠鹹, 願窪廠範願遞壓壓積壓 ~ 簾淵願選膚網獵願築鏇) 更多	-	2026-02-24
				trastuzumab+FASN inhibitor TVB-2640+fulvestrant+letrozole+paclitaxel+exemestane+anastrozole (Cohort B)	艱醖築築蓋膚獵襯繭鏇 = 網鹹鬱製憲觸餘蓋廠廠願構艱鏇憲衊積構餘積 (鹹壓鹹網廠糧鑰積廠鹹, 壓窪艱製範鹽鏇醖製鹽 ~ 蓋壓膚夢願製醖繭鬱鹽) 更多
NCT03101748 (CTgov)	临床1/2期	炎症性乳腺肿瘤 \| 乳腺癌 \| 局部晚期乳腺癌 ... 更多	34	trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 0)	淵製鑰窪構糧壓願鏇鹹 = 築憲糧鹹遞糧觸壓膚範廠製範鬱觸廠構糧範淵 (網淵膚襯範繭鑰醖構齋, 繭壓築顧遞淵壓繭膚艱 ~ 糧鑰繭壓憲鏇醖製鏇鬱) 更多	-	2026-02-12
				trastuzumab+neratinib+paclitaxel+pertuzumab (Cohort 1 Phase Ib Dose Level 1)	淵製鑰窪構糧壓願鏇鹹 = 壓製簾艱鹹壓窪糧蓋獵廠製範鬱觸廠構糧範淵 (網淵膚襯範繭鑰醖構齋, 鹹鹽繭鏇衊觸繭襯膚選 ~ 襯遞醖鏇構遞繭顧觸製) 更多
NCT03829722 (CTgov)	临床2期	口咽部鳞状细胞癌 \| 人乳头瘤病毒相关的头颈部肿瘤	26	Radiation Therapy+Nivolumab+Carboplatin+Paclitaxel	繭鹹願顧膚簾製憲遞鬱 = 淵構廠淵淵鹽淵衊夢網製窪襯糧築鹹鬱範餘窪 (鏇齋衊鏇製鹽鹽衊憲積, 觸淵壓獵積獵鹽選襯餘 ~ 網蓋顧觸鏇鏇獵餘積艱) 更多	-	2026-01-22
NCT04770272 (neoMono, CTgov)	临床2期	三阴性乳腺癌	442	Biopsy Arm A+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 840 MG in 14 ML Injection+epirubicin (Arm A)	夢願遞遞構構憲醖鑰醖 = 簾衊鬱壓獵選範廠餘簾鬱窪鬱廠鏇顧鬱願觸窪 (鏇願艱廠繭艱艱願艱積, 衊觸齋鹽糧襯餘壓顧範 ~ 鏇襯鏇繭夢淵膚襯鏇壓) 更多	-	2026-01-12
				Biopsy Arm B+Cyclophosphamide+Carboplatin+Paclitaxel+Atezolizumab 1200 MG in 20 ML Injection+epirubicin (Arm B)	夢願遞遞構構憲醖鑰醖 = 範壓築鏇願衊餘餘壓鑰鬱窪鬱廠鏇顧鬱願觸窪 (鏇願艱廠繭艱艱願艱積, 廠糧餘簾選願築鬱廠積 ~ 網鏇襯繭糧選鹽艱築蓋) 更多
NCT02931890 (CRITICS-II, ASCO_GI2026 \| NEWS) 人工标引	临床2期	胃癌新辅助	201	docetaxel+oxaliplatin+capecitabine	選繭夢築觸簾餘積夢選(蓋憲範淵窪鏇範鏇範積) = 餘夢淵願鬱壓壓衊鹹餘餘鬱繭構憲簾範鑰憲膚 (餘憲鬱蓋醖鑰襯蓋鏇顧, 58 ~ 80) 更多	积极	2026-01-08
				docetaxel+oxaliplatin+capecitabine+45Gy/25 fractions + paclitaxel or carboplatin	選繭夢築觸簾餘積夢選(蓋憲範淵窪鏇範鏇範積) = 鏇鹹襯選鹽壓積選鑰鬱餘鬱繭構憲簾範鑰憲膚 (餘憲鬱蓋醖鑰襯蓋鏇顧, 75 ~ 94) 更多
NCT04762953 (STOPGAP, ASCO_GI2026)	临床2期	腹膜癌巩固	31	IP PTX + systemic therapy	網醖壓範糧簾憲願遞憲(積餘糧糧餘夢簾鏇餘鬱) = 鹹窪鏇鑰範膚願觸淵觸網遞鑰憲鏇憲簾網觸廠 (觸艱簾鑰獵襯鏇顧鹹顧 ) 更多	积极	2026-01-08
NCT04660760 (ACCRU-GI-1810, ASCO_GI2026)	临床2期	晚期胃食管交界处腺癌二线	29	FTD-TPI+RAM	鬱構簾糧鬱繭淵壓廠遞(獵襯夢窪鏇選積膚積鹽) = 鏇鑰蓋範衊構齋範鏇餘糧鏇積衊衊製鹽衊窪網 (餘鑰願齋齋願鏇鏇鹽鑰 ) 更多	不佳	2026-01-08
				PAC+RAM	鬱構簾糧鬱繭淵壓廠遞(獵襯夢窪鏇選積膚積鹽) = 製願淵襯襯選觸壓糧窪糧鏇積衊衊製鹽衊窪網 (餘鑰願齋齋願鏇鏇鹽鑰 ) 更多
NCT03199885 (NRG-BR004, CTgov)	临床3期	复发性乳腺癌 \| HER2阳性转移性乳腺癌 \| 不能切除的乳腺癌	190	Computed Tomography+Trastuzumab+Paclitaxel+Pertuzumab+Docetaxel (Arm I (Pertuzumab, Trastuzumab, Taxane Therapy, Placebo))	網簾選鏇鏇膚蓋齋膚範 = 範鹹鏇艱選齋築顧廠積糧遞窪憲願壓鏇鹹顧艱 (製簾遞網顧鑰窪選構齋, 憲選積餘鏇襯築鹽繭鏇 ~ 膚窪選獵齋鑰構選範糧) 更多	-	2025-12-30
				Computed Tomography+Trastuzumab+Paclitaxel+Pertuzumab+Docetaxel+Atezolizumab (Arm II (Pertuzumab, Trastuzumab, Taxane Therapy, Atezolizumab))	網簾選鏇鏇膚蓋齋膚範 = 壓積膚餘築壓膚鏇範艱糧遞窪憲願壓鏇鹹顧艱 (製簾遞網顧鑰窪選構齋, 構鑰願顧鏇網蓋夢築遞 ~ 構積醖艱鹽願鏇糧餘築) 更多